Aptus Pharma Limited (BOM:544529)
India · Delayed Price · Currency is INR 339.90
+6.65 (2.00%)
At close: Sep 11, 2026
Aptus Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 465.75 | 245.58 | 178.57 | 138.97 | 105.07 | |
Revenue Growth | 89.65% | 37.52% | 28.49% | 32.27% | 106.18% |
Cost of Revenue | 213.99 | 90.77 | 68.26 | 47.63 | 38.31 |
Gross Profit | 251.76 | 154.81 | 110.31 | 91.35 | 66.76 |
Selling, General & Admin | 128.82 | 70.72 | 43.21 | 30.37 | 26.39 |
Other Operating Expenses | 48.4 | 35.6 | 51.2 | 54.41 | 37.05 |
Operating Expenses | 181.3 | 108.97 | 96.53 | 86.58 | 64.39 |
Operating Income | 70.46 | 45.84 | 13.78 | 4.76 | 2.37 |
Interest Expense | -7.87 | -3.13 | -1.6 | -0.99 | -0.84 |
Interest & Investment Income | 1.34 | 0.77 | 0.25 | - | - |
Other Non Operating Income (Expenses) | -0.18 | -1.53 | -0.79 | -0.44 | -0.07 |
EBT Excluding Unusual Items | 63.75 | 41.95 | 11.64 | 3.33 | 1.46 |
Pretax Income | 63.75 | 41.95 | 11.64 | 3.33 | 1.46 |
Income Tax Expense | 17.55 | 10.96 | 3.04 | 0.9 | 0.45 |
Net Income | 46.2 | 31 | 8.6 | 2.43 | 1.01 |
Net Income to Common | 46.2 | 31 | 8.6 | 2.43 | 1.01 |
Net Income Growth | 49.05% | 260.45% | 254.23% | 140.83% | 163.41% |
Shares Outstanding (Basic) | 15 | 12 | 4 | 2 | 2 |
Shares Outstanding (Diluted) | 15 | 12 | 4 | 2 | 2 |
Shares Change | 22.08% | 224.21% | 105.42% | -0.02% | 16.87% |
EPS (Basic) | 3.11 | 2.55 | 2.29 | 1.33 | 0.55 |
EPS (Diluted) | 3.11 | 2.55 | 2.29 | 1.33 | 0.55 |
EPS Growth | 22.13% | 11.13% | 72.44% | 140.87% | 125.39% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -77.89 | -24.6 | -25.04 | -5.34 | - |
Free Cash Flow Per Share | -5.25 | -2.02 | -6.68 | -2.92 | - |
Gross Margin | 54.05% | 63.04% | 61.77% | 65.73% | 63.54% |
Operating Margin | 15.13% | 18.67% | 7.72% | 3.43% | 2.26% |
Profit Margin | 9.92% | 12.62% | 4.82% | 1.75% | 0.96% |
Free Cash Flow Margin | -16.72% | -10.02% | -14.02% | -3.84% | - |
EBITDA | 74.54 | 48.49 | 15.92 | 6.57 | 2.8 |
EBITDA Margin | 16.00% | 19.75% | 8.92% | 4.73% | 2.67% |
D&A For EBITDA | 4.08 | 2.65 | 2.15 | 1.81 | 0.43 |
EBIT | 70.46 | 45.84 | 13.78 | 4.76 | 2.37 |
EBIT Margin | 15.13% | 18.67% | 7.72% | 3.43% | 2.26% |
Effective Tax Rate | 27.53% | 26.11% | 26.10% | 27.10% | 31.06% |
Revenue as Reported | 467.08 | 246.36 | 178.82 | 138.97 | 105.07 |
Advertising Expenses | 74.32 | 33.59 | 20.61 | 15.24 | 17.21 |